

**Neurobiology:**  
**Opposite Effects of KCTD Subunit  
Domains on GABA  $\beta$  Receptor-mediated  
Desensitization**

NEUROBIOLOGY

Riad Seddik, Stefan P. Jungblut, Olin K.  
Silander, Mathieu Rajalu, Thorsten Fritzius,  
Valérie Besseyrias, Valérie Jacquier, Bernd  
Fakler, Martin Gassmann and Bernhard  
Bettler

*J. Biol. Chem.* 2012, 287:39869-39877.

doi: 10.1074/jbc.M112.412767 originally published online October 3, 2012

---

Access the most updated version of this article at doi: [10.1074/jbc.M112.412767](https://doi.org/10.1074/jbc.M112.412767)

Find articles, minireviews, Reflections and Classics on similar topics on the [JBC Affinity Sites](http://www.jbc.org/).

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 46 references, 26 of which can be accessed free at  
<http://www.jbc.org/content/287/47/39869.full.html#ref-list-1>

# Opposite Effects of KCTD Subunit Domains on GABA<sub>B</sub> Receptor-mediated Desensitization\*

Received for publication, August 23, 2012, and in revised form, October 2, 2012. Published, JBC Papers in Press, October 3, 2012, DOI 10.1074/jbc.M112.412767

Riad Seddik<sup>†1,2</sup>, Stefan P. Jungblut<sup>†1</sup>, Olin K. Silander<sup>§</sup>, Mathieu Rajalu<sup>‡</sup>, Thorsten Fritzius<sup>‡</sup>, Valérie Besseyrias<sup>‡</sup>, Valérie Jacquier<sup>‡</sup>, Bernd Fakler<sup>¶||</sup>, Martin Gassmann<sup>‡3</sup>, and Bernhard Bettler<sup>‡4</sup>

From the <sup>†</sup>Department of Biomedicine, University of Basel, 4056 Basel, Switzerland, the <sup>§</sup>Core Program Computational and Systems Biology, Biozentrum, University of Basel, 4056 Basel, Switzerland, the <sup>¶</sup>Institute of Physiology II, University of Freiburg, 79108 Freiburg, Germany, and the <sup>||</sup>Center for Biological Signaling Studies (bloss), 79104 Freiburg, Germany

**Background:** GABA<sub>B</sub> receptors in the brain assemble with auxiliary KCTD8, 12, 12b, and 16 subunits that influence the receptor response in distinct ways.

**Results:** Distinct KCTD domains exert opposing effects on desensitization of the receptor response.

**Conclusion:** KCTD12 and -12b acquired desensitizing properties by disposing of a C-terminal inhibitory domain.

**Significance:** This study defines the domains and motifs in KCTD proteins that generate functionally distinct GABA<sub>B</sub> receptor subtypes.

GABA<sub>B</sub> receptors assemble from principle and auxiliary subunits. The principle subunits GABA<sub>B1</sub> and GABA<sub>B2</sub> form functional heteromeric GABA<sub>B(1,2)</sub> receptors that associate with homotetramers of auxiliary KCTD8, -12, -12b, or -16 (named after their K<sup>+</sup> channel tetramerization domain) subunits. These auxiliary subunits constitute receptor subtypes with distinct functional properties. KCTD12 and -12b generate desensitizing receptor responses while KCTD8 and -16 generate largely non-desensitizing receptor responses. The structural elements of the KCTDs underlying these differences in desensitization are unknown. KCTDs are modular proteins comprising a T1 tetramerization domain, which binds to GABA<sub>B2</sub>, and a H1 homology domain. KCTD8 and -16 contain an additional C-terminal H2 homology domain that is not sequence-related to the H1 domains. No functions are known for the H1 and H2 domains. Here we addressed which domains and sequence motifs in KCTD proteins regulate desensitization of the receptor response. We found that the H1 domains in KCTD12 and -12b mediate desensitization through a particular sequence motif, T/NFLEQ, which is not present in the H1 domains of KCTD8 and -16. In addition, the H2 domains in KCTD8 and -16

inhibit desensitization when expressed C-terminal to the H1 domains but not when expressed as a separate protein *in trans*. Intriguingly, the inhibitory effect of the H2 domain is sequence-independent, suggesting that the H2 domain sterically hinders desensitization by the H1 domain. Evolutionary analysis supports that KCTD12 and -12b evolved desensitizing properties by liberating their H1 domains from antagonistic H2 domains and acquisition of the T/NFLEQ motif.

GABA<sub>B</sub> receptors are the G-protein-coupled receptors (GPCRs)<sup>5</sup> for GABA, the main inhibitory neurotransmitter in the central nervous system. They are widely distributed throughout the brain and have been implicated in a variety of disorders including cognitive impairments, addiction, anxiety, depression, and epilepsy (1, 2). GABA<sub>B</sub> receptors activate G<sub>α<sub>i/o</sub></sub>-type G-proteins that inhibit adenylyl cyclase and efficiently gate ion channels (3–5). Native GABA<sub>B</sub> receptors are known to comprise principal and auxiliary subunits that influence receptor properties in distinct ways (5, 6). The principal subunits form two core receptors, GABA<sub>B(1a,2)</sub> and GABA<sub>B(1b,2)</sub> that bind all GABA<sub>B</sub> ligands, couple to G-proteins and regulate classical GABA<sub>B</sub> receptor effectors, including G-protein coupled inwardly rectifying K<sup>+</sup> channels (GIRK channels, also known as Kir3 channels) and voltage-gated Ca<sup>2+</sup> channels. The auxiliary subunits KCTD8, -12, -12b, and -16 are cytosolic proteins that modulate agonist potency and kinetic properties of the receptor response in distinct ways (6). In particular, KCTD12 or -12b produce fast desensitizing GABA<sub>B</sub> receptor-mediated Kir3 currents characterized by time constants of seconds while KCTD8 and -16 produce currents with little desensitization. The molecular determinants in the KCTD proteins and the mechanism underlying these kinetic differences in GABA<sub>B</sub> responses

\* This work was supported by grants from the Swiss National Science Foundation (3100A0-117816), the National Center for Competence in Research (NCCR) "Synapsy, Synaptic Bases of Mental Health Disease" (to B. B.), the European Community's Seventh Framework Programme (FP7/2007-2013) under Grant Agreement 201714 (to B. B.), an Ambizione fellowship from the Swiss National Science Foundation (to O. K. S.), and a Marie Heim-Vögtlin fellowship from the Swiss National Science Foundation (to V. J.).

<sup>1</sup> Both authors contributed equally to this work.

<sup>2</sup> Present address: Laboratoire de Physiologie et Physiopathologie du Système Nerveux Somato-moteur et Neurovégétatif (PPSN), EA 4674 Aix-Marseille Université (AMU), Faculté des Sciences et Techniques St. Jérôme, BP 352, F-13397 Marseille cedex 20, France.

<sup>3</sup> To whom correspondence may be addressed: Department of Biomedicine, University of Basel, Pharmazentrum, Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland. Tel.: +41-61-267-1641; Fax: +41-61-267-1628; E-mail: martin.gassmann@unibas.ch.

<sup>4</sup> To whom correspondence may be addressed: Department of Biomedicine, University of Basel, Pharmazentrum, Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland. Tel.: +41-61-267-1632; Fax: +41-61-267-1628; E-mail: bernhard.bettler@unibas.ch.

<sup>5</sup> The abbreviations used are: GPCR, G-protein-coupled receptor; KCTD, K<sup>+</sup> channel tetramerization domain; GIRK, G-protein activated inwardly rectifying K<sup>+</sup>; Kir, K<sup>+</sup> inwardly rectifying; GRK, G-protein-coupled receptor kinase; RGS, regulator of G-protein signaling; BTB, bric-a-brac, tramtrak, and broad complex; Luc, Luciferase.

## Regulatory Domains in Auxiliary GABA<sub>B</sub> Receptor Subunits

are unknown. Importantly, fast desensitization of GABA<sub>B</sub> receptor-mediated K<sup>+</sup> currents is also observed with neurons (7, 8) expressing KCTD12 (9). However, it has not been specifically addressed whether this fast desensitization is due to the presence of KCTD12 in the receptor. In addition, desensitization of GABA<sub>B</sub> responses was shown to be regulated by GRK4 (10), RGS proteins (11–14) or phosphorylation of the GABA<sub>B2</sub> subunit (15, 16).

KCTD8, -12, -12b, and -16 constitute a subfamily of the KCTD family of proteins. All KCTD proteins contain a N-terminal bric-a-brac, tramtrak, and broad complex (BTB) domain that is most similar in sequence to the T1 tetramerization domain of voltage-gated K<sup>+</sup> channels (17, 18). In voltage-gated K<sup>+</sup> channels, T1 domains are responsible for assembly of the four subunits around a central channel pore (19). Likewise, the T1 domains of auxiliary GABA<sub>B</sub> receptor subunits assemble into a homotetramer that tightly binds to the C-terminal intracellular domain of GABA<sub>B2</sub> (6). All auxiliary GABA<sub>B</sub> receptor subunits contain a second conserved domain, designated the H1 homology domain, which is separated from the T1 domain by a non-conserved linker region. KCTD8 and -16 comprise an additional C-terminal conserved H2 homology domain. The H1 and H2 domains exhibit no sequence similarities to each other or to other proteins, thus giving no hints regarding their functions (5). Here we studied the influence of the H1 and H2 domains on desensitization of the receptor response. We found that H1 and H2 domains have opposite effects on the desensitization kinetics of the receptor response. The evolutionary analysis of protein sequences suggests that KCTD12 and -12b acquired desensitizing properties by disposing of their inhibitory H2 domains and selecting the T/NFLEQ motif in their H1 domains.

### EXPERIMENTAL PROCEDURES

**Generation of Expression Plasmids**—All KCTD cDNAs were cloned in-frame with the N-terminal tag of three c-Myc epitopes (MEQKLISEEDLGEQKLISEEDLLEQKLISEEDLAAEF) into the cytomegalovirus-based expression vector pCI (Promega). Mutant constructs were generated using overlap extension PCR (20). To generate 12T1–16H1H2, residues Arg<sup>207</sup> to Glu<sup>327</sup> in KCTD12 were replaced by residues Arg<sup>161</sup> to Leu<sup>427</sup> of KCTD16. To generate 16T1–12H1, residues Arg<sup>161</sup> to Leu<sup>427</sup> in KCTD16 were replaced by residues Arg<sup>207</sup> to Glu<sup>327</sup> of KCTD12. To generate 12–16H2, residues Pro<sup>280</sup> to Leu<sup>427</sup> of KCTD16 were added in-frame at the C terminus of KCTD12. To generate 16H2, residues Pro<sup>280</sup> to Leu<sup>427</sup> of KCTD16 were cloned in-frame with the N-terminal c-Myc epitopes. To generate 16ΔH2, a stop codon was inserted after residue Glu<sup>279</sup> in KCTD16. To generate 12–16H2Δ60 and 12–16H2Δ113, a stop codon was inserted in 12–16H2 after residues Thr<sup>367</sup> and Cys<sup>314</sup>, respectively. To generate 12-Luc and 12-Venus, the cDNA of the *Renilla reniformis* Luciferase (Luc) or the GFP variant Venus from *Aequorea victoria* (Venus) was added in-frame via a flexible peptide linker (GGGSGGGGS) to the C terminus of KCTD12. To generate Luc-12 and Venus-12, the cDNA of Luc and Venus, respectively, was added in-frame via a GGGSGGGGS peptide linker to the N terminus of KCTD12. N-terminally tagged KCTD12 constructs did not contain the


three c-Myc epitope tag. To generate 16T1–16/12H1G, residues Gly<sup>244</sup> to Glu<sup>279</sup> in 16ΔH2 were exchanged by residues Gly<sup>290</sup> to Glu<sup>327</sup> of KCTD12. To generate 16T1–16/12H1N residues Lys<sup>231</sup> to Glu<sup>279</sup> in KCTD16ΔH2 were exchanged by residues Asn<sup>277</sup> to Glu<sup>327</sup> of KCTD12. To generate 8ΔH2, a stop codon was inserted after residue Pro<sup>325</sup> in KCTD8. To generate 8ΔH2F, Tyr<sup>278</sup> in the H1 domain of 8ΔH2 was mutated to Phe. To generate 16ΔH2F, His<sup>232</sup> in the H1 domain of 16ΔH2 was mutated to Phe. To generate 16ΔH2NFQ, Lys<sup>231</sup>, His<sup>232</sup>, and Arg<sup>235</sup> in the H1 domain of 16ΔH2 were mutated to Asn, Phe, and Gln, respectively. To generate 12H, Phe<sup>278</sup> in the H1 domain of KCTD12 was mutated to His. To generate 12KHR, Asn<sup>277</sup>, Phe<sup>278</sup>, and Gln<sup>281</sup> in the H1 domain of KCTD12 were mutated to Lys, His, and Arg, respectively.

**Cell Culture**—CHO-K1 cells stably expressing human GABA<sub>B1b</sub> and rat GABA<sub>B2</sub> were maintained in Dulbecco's modified Eagle's medium (DMEM) with 500 μM L-glutamine, 40 μg/ml L-proline, 0.5 mg/ml G418, 0.25 mg/ml zeocine, and 10% FCS in a humidified atmosphere of 5% CO<sub>2</sub> at 37 °C (21). Cells were transfected in 24-well plates at 80–90% confluency using 3 μl of Lipofectamine 2000 (Invitrogen) and 1.2 μg of Kir3.1/3.2 concatamer in pcDNA3.1 (22), 2-μg KCTD constructs in pCI and 0.3 μg of pEGFP-N1 (Clontech) to visualize transfected cells. 6 h after transfection the cells were plated onto plastic coverslips (Thermanox, Nalge Nunc International) at a dilution of 1:5 in 35 mm dishes and used for electrophysiological recordings 24–48 h later.

HEK293T cells (ATCC CRL-11268) were cultured in DMEM supplemented with 10% FCS and 500 μM L-glutamine in a humidified atmosphere of 5% CO<sub>2</sub> at 37 °C. Cells were transfected at 80–90% confluency using Lipofectamine 2000. For transfection in 6-cm dishes, 12 μl of Lipofectamine and 1.5 μg of plasmid DNA were used. Cells were harvested after 48 h for co-immunoprecipitation and Western blot analysis.

**Co-immunoprecipitation and Western Blot Analysis**—HEK293T cells were harvested, washed in PBS, and subsequently lysed in a Nonidet P-40 buffer (100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 20 mM Tris/HCl, pH 7.4) supplemented with complete EDTA-free protease inhibitor mixture (Roche). After rotation for 10 min at 4 °C, the lysates were cleared by centrifugation at 16,000 × g for 10 min at 4 °C. Lysates were then directly used for Western blot analysis or precleared for 1 h using 30 μl of a 1:1 mixture of protein-A- and protein-G-agarose (GE Healthcare) to be used in co-immunoprecipitation experiments. Precleared lysates were immunoprecipitated with anti-GB2 antibody (Millipore, AB5394, 1 μg, 3 h of incubation at 4 °C) and protein-A- and protein-G-Sepharose (10 μl, 1 h of incubation). Lysates and immunoprecipitates were resolved using standard SDS-PAGE, and probed with the primary antibodies mouse anti-Myc (F1804, Sigma, 1:1000), mouse anti-*R. reniformis* Luciferase (MAB4410, Millipore, 1:2000) or rabbit anti-GFP (A11122, Invitrogen, 1:1000) and peroxidase-coupled secondary antibodies (NA931V and NA9340V, Amersham Biosciences, 1:10000). The antibody incubation was in 5% nonfat dry milk in PBS containing 0.1% Tween-20. The chemiluminescence detection kit (Pierce) was used for visualization.





**FIGURE 1. H1 and H2 domains have opposite effects on KCTD12-mediated desensitization of the GABA<sub>B</sub> response.** *A* and *B*, representative traces of GABA<sub>B</sub>-activated Kir3 currents recorded at  $-50$  mV from CHO cells co-expressing GABA<sub>B(1b,2)}</sub>, Kir3 channels and KCTD proteins. In the presence of KCTD16 or 12T1-16H1H2 Kir3 currents exhibit modest desensitization in response to continuous GABA (0.1 mM for 40 s) application, comparable to the current desensitization observed without KCTD proteins (wo KCTD). In the presence of KCTD12 or 16T1-12H1, GABA<sub>B</sub>-activated Kir3 currents exhibit significantly increased desensitization. The scheme depicts the T1 tetramerization domains and H1 and H2 homology domains of KCTD12 (gray) and KCTD16 (white). *C*, bar graph summarizing the desensitization of Kir3 currents in the absence and presence of KCTD proteins. Data are expressed as mean  $\pm$  S.D.; \*\*\*,  $p < 0.001$  compared with cells without KCTD proteins (Dunnett's multiple comparison test). *D*, Western blot analysis of wild-type and chimeric KCTD proteins using anti-Myc antibodies. The molecular mass is indicated on the left (in kDa).

**Electrophysiology**—EGFP-expressing CHO cells were identified via epifluorescence using a FITC filter set and patched under oblique illumination optics (BX51WI; Olympus). Kir3 currents were recorded at 30–32 °C in artificial cerebrospinal fluid containing (in mM): 119 NaCl, 2.7 KCl, 1.3 MgCl<sub>2</sub>, 2.5 CaCl<sub>2</sub>, 1 NaH<sub>2</sub>PO<sub>4</sub>, 26.2 NaHCO<sub>3</sub>, 11 glucose, pH 7.3, equilibrated with 95% O<sub>2</sub>/5% CO<sub>2</sub>. Patch pipettes were pulled from borosilicate glass capillaries (resistance of 3–5 M $\Omega$ ) and filled with a solution containing (in mM): 140 K-gluconate, 4 NaCl, 5 HEPES, 2 MgCl<sub>2</sub>, 1.1 EGTA, 2 Na<sub>2</sub>-ATP, 5 phosphocreatine, 0.6 Na<sub>3</sub>-GTP, at pH 7.25 (adjusted with KOH). GABA<sub>B</sub> responses were evoked at  $-50$  mV by fast application of 100  $\mu$ M GABA (Sigma) for 40 s with a pressure pipette (standard patch pipette; 3 PSI, Picospritzer III, Intracell).

Data were acquired with a MultiClamp 700B (Molecular Devices), low-pass filtered at 2 kHz and digitized at 10 kHz using a Digidata 1322A interface (Molecular Devices) driven by pClamp 10.2 software. Whole-cell currents were analyzed using Clampfit 10.2 software (Molecular Devices). All values are expressed as mean  $\pm$  S.D. Data were analyzed by one-way ANOVA followed by Dunnett's test for pairwise comparison with the control group (Igor Pro software).  $p$  values  $< 0.05$  were considered as statistically significant.

**Protein Alignments and Phylogenetic Trees**—For the tree of all KCTD proteins, all annotated human KCTD protein sequences were used to query the NCBI nr protein database with blastp and all sequences with an e-value less than 1e-5 were retrieved and aligned using MUSCLE (23). Deeply diverging sequences that could not be reliably aligned were discarded (this set included all KCTD20 sequences). The sequences were re-aligned, and used as input into the tree-building program MrBayes 3.0 (24). The tree shown in Fig. 5A has been pruned to retain only the KCTDs from *Mus musculus*.

For the tree of KCTD8, -12, -12b, and -16, the H1 domain from human KCTD16 was used to query the NCBI nr protein database with blastp. The nucleotide sequences from all hits with an e-value less than 1e-10 were retrieved and aligned using MUSCLE. GBLOCKS (25) was used to retain only well-aligned blocks. This alignment was used as input into MrBayes. The tree shown in Fig. 5B has been pruned to retain only the KCTDs of *M. musculus*, *Danio rerio*, *Branchiostoma floridae*, *Drosophila melanogaster*, and *Caenorhabditis elegans*.

For the alignment of GABA<sub>B2</sub> C termini, the human GABA<sub>B2</sub> was used to query the NCBI nr protein database with blastp, and sequences from several species were aligned using MUSCLE. The C termini of non-vertebrates do not align with vertebrates and are not shown in the alignment.

The alignment of vertebrate KCTD H2 domain sequences was performed on the most recent ENSEMBL draft genomes of the species indicated. These sequences were blasted with the KCTD12b protein sequence from *Oryzias latipes* using tblastn. All hits which had H2-like sequences within the same contig were retained. All potential H2-like open reading frames were separated by 9.4 (*Tetraodon nigroviridis*) to 103 kb (*Ornithorhynchus anatinus*) from the open reading frame containing the T1 and H1 domains. The retained sequences grouped with KCTD12b and not KCTD8 or -16, suggesting that they are indeed KCTD12b sequences.

## RESULTS

**Distinct KCTD Protein Domains Influence Desensitization of the GABA<sub>B</sub> Receptor Response**—KCTD subunits are built from T1, H1, and H2 domains, whereby only KCTD8 and 16 contain a H2 domain. The domain organization of KCTD12 and KCTD16 is illustrated in Fig. 1A. Previous work indicated that the lack of the H2 domain in KCTD12 and -12b correlates with strong

## Regulatory Domains in Auxiliary GABA<sub>B</sub> Receptor Subunits


desensitization of the receptor response (6). We therefore hypothesized that H1 domains facilitate and H2 domains inhibit desensitization. We tested this hypothesis using patch-clamp electrophysiology and CHO cells expressing GABA<sub>B(1b,2)</sub> receptors and effector Kir3 channels in the presence and absence of wild-type and mutant KCTD proteins. In the absence of KCTD proteins, activation of GABA<sub>B</sub> receptors for 40 s by GABA (0.1 mM) elicited Kir3 currents that slightly decreased in amplitude over time (Fig. 1A). The relative desensitization of GABA-activated Kir3 currents was calculated as the reduction in amplitude measured at the end of the GABA application normalized to the peak amplitude (Fig. 1C). In agreement with reported results (6), co-expression of KCTD12 significantly increased the desensitization of GABA-activated Kir3 currents, while KCTD16 had no significant effect on desensitization (Fig. 1, A and C;  $p < 0.001$ , compared with cells without KCTD). To identify the KCTD12 domain(s) responsible for desensitization we generated two chimeric proteins, 16T1–12H1 and 12T1–16H1H2, in which the H1 domain of KCTD12 and the H1/H2 domains of KCTD16 are swapped. The desensitization of GABA-activated Kir3 currents was significantly increased in cells expressing the chimeric protein 16T1–12H1 but not in cells expressing 12T1–16H1H2 (Fig. 1, B and C). Of note, both chimeric proteins contained the linker region of KCTD16. Western blot analysis confirmed that the chimeric KCTD proteins were expressed (Fig. 1D). In summary, these data show that the desensitizing properties of KCTD12 segregate with its H1 domain.

We next tested whether the H2 domain exerts an inhibitory influence on desensitization. We generated the mutant 12–16H2 with the H2 domain of KCTD16 attached to the C terminus of KCTD12. 12–16H2 lacks desensitizing properties, in line with a dominant inhibitory effect of the H2 domain on KCTD12-mediated desensitization (Fig. 2, A and D). However, removal of the H2 domain from KCTD16 in the mutant 16ΔH2 does not produce a desensitizing KCTD protein (Fig. 2, A and D). Therefore, the H1 domain of KCTD16 is not sufficient for desensitization and differs in its functional properties from the H1 domain of KCTD12.

We next addressed whether the H2 domain of KCTD16 not only prevents KCTD12-mediated desensitization *in cis* but also *in trans*. When the H2 domain of KCTD16 is co-expressed with KCTD12 as an independent 16H2 protein GABA<sub>B</sub>-activated Kir3 currents still desensitize (KCTD12 + 16H2; Fig. 2, A and D;  $p < 0.001$ , compared with cells without KCTD). Expression of the 16H2 protein was confirmed by Western blot analysis (Fig. 2E). Therefore, the H2 domain only prevents KCTD12-mediated desensitization *in cis* but not *in trans*. In order to map the minimal size of the H2 domain preventing desensitization *in cis*, we generated C-terminal truncations of the chimeric 12–16H2 protein. Truncation of 60 of the 148 amino acid residues of the H2 domain in the 12–16H2Δ60 protein is insufficient to restore desensitization (Fig. 2, B and D). However, truncation of 113 amino acid residues in the 12–16H2Δ113 protein fully restored desensitization (Fig. 2, B and D). This shows that the size of the H2 domain is critical for inhibition of KCTD12-mediated desensitization. We tested whether adding KCTD-unrelated protein domains to the C terminus of KCTD12 also

prevents desensitization. Adding Luciferase (Luc) or the GFP variant Venus to the C terminus of KCTD12 in the 12-Luc and 12-Venus proteins completely prevented desensitization, suggestive of a sequence-unrelated steric hindrance of desensitization (Fig. 2, C and D). The 12–16H2, 12-Luc and 12-Venus proteins co-immunoprecipitate with GABA<sub>B2</sub> (Fig. 2F). This demonstrates that the lack of desensitization of these proteins is not due to a lack of association with the receptor. Adding the Luc or Venus domains to the N terminus of KCTD12 in the Luc-12 and Venus-12 proteins did not prevent desensitization, showing that only protein domains C-terminal of the H1 domain are inhibitory (Fig. 2, C and D).

*The Desensitization Motif of H1 Domains*—We next determined the amino acid residues in the H1 domain of KCTD12 that differ from KCTD16 and mediate the desensitization. Sequence alignment revealed significant differences between KCTD12 and KCTD16 within the C-terminal half of their H1 domains (Fig. 3A). We therefore tested whether desensitizing properties can be transferred from KCTD12 to KCTD16 by replacing the C-terminal half of the H1 domain of KCTD16 with the corresponding sequence of KCTD12. We generated the two chimeric proteins 16T1–16/12H1G and 16T1–16/12H1N in which the 36 and 49 C-terminal residues, respectively, in the H1 domain of KCTD16 were replaced with those of KCTD12. In addition, we omitted in these chimeric proteins the H2 domain of KCTD16 to avoid its inhibitory effect on desensitization. The desensitization of GABA<sub>B</sub> receptor-activated Kir3 currents was small in CHO cell expressing 16T1–16/12H1G protein or the KCTD16. In contrast, cells expressing the 16T1–16/12H1N protein exhibited significantly more desensitization (Fig. 3, B and C;  $p < 0.001$ , compared with KCTD16). This result shows that the ability to desensitize GABA<sub>B</sub>-activated Kir3 currents can be transferred from the KCTD12 to KCTD16 H1 domain by exchanging the 49 C-terminal residues of the H1 domains. In addition, the result points at the 13 amino acid residues between Asn<sup>277</sup> and Ser<sup>289</sup> in the H1 domain of KCTD12 as being critical for desensitization. Sequence alignment of these 13 amino acid residues in KCTD8, 12, 12b, and 16 reveals that only Tyr<sup>278</sup> in KCTD8 is not identical or highly conserved with either KCTD12 or KCTD12b, which harbor an Phe residue at this position (Fig. 4A). We therefore addressed whether substitution of Tyr<sup>278</sup> in KCTD8 with Phe renders the H1 domain in KCTD8 desensitizing. We first established that deletion of the H2 domain of KCTD8 in the 8ΔH2 protein was insufficient to convert KCTD8 into a desensitizing subunit (Fig. 4, B and D), similar as already observed with KCTD16 (Fig. 2). Strikingly, substitution of Tyr<sup>278</sup> with Phe in the 8ΔH2F protein generated receptor responses with increased desensitization (Fig. 4, B and D;  $p < 0.05$ , compared with cells without KCTD). KCTD16 exhibits additional sequence divergence with KCTD12 and KCTD12b in the 13 amino acid residues under scrutiny (Fig. 4A). Accordingly, single amino acid substitution of His<sup>232</sup>, the residue homologous to Tyr<sup>278</sup> in KCTD8, with Phe in the 16ΔH2F protein was insufficient to render the H1 domain of KCTD16 desensitizing (Fig. 4, C and D). However, additional substitution of two neighboring non-conserved residues (Asn for Lys<sup>231</sup> and Gln for Arg<sup>235</sup>) in 16ΔH2NFQ also rendered the H1 domain of KCTD16 desensitizing (Fig. 4, C



**FIGURE 2. The H2 domain inhibits desensitization by the KCTD proteins.** *A–C*, representative traces of GABA<sub>B</sub>-activated Kir3 currents recorded at  $-50$  mV from CHO cells co-expressing GABA<sub>B(1b,2)}</sub>, Kir3 channels, and KCTD proteins. In the presence of 12–16H2, a chimeric protein consisting of KCTD12 and the H2 domain of KCTD16, Kir3 currents exhibit modest desensitization. In contrast, when the H2 domain of KCTD16 was co-transfected with KCTD12 (KCTD12 + 16H2), currents show significantly increased desensitization. This indicates that the H2 domain exerts an inhibitory influence on desensitization *in cis* but not *in trans*. However, KCTD16 lacking its H2 domain (16ΔH2) does not induce current desensitization (*A*). Deletion of 113 amino acids (12–16H2Δ113) but not of 60 amino acids (12–16H2Δ60) from the C terminus of the H2 domain in 12–16H2 restored the ability of the KCTD protein to induce current desensitization (*B*). Tagging KCTD12 with Luciferase at the C terminus (12-Luc) but not at the N terminus (Luc-12) eliminated its ability to induce desensitization (*C*). *D*, bar graph summarizing the desensitization of Kir3 currents in the absence and presence of KCTD proteins; *wo KCTD*, without KCTD. Data are expressed as mean  $\pm$  S.D.;  $***$ ,  $p < 0.001$  compared with cells without KCTD (Dunnett's multiple comparison test). *E*, Western blot analysis of chimeric, truncated, or tagged KCTD proteins using anti-myc, anti-Luc or anti-GFP antibodies. The molecular mass is indicated on the left (in kDa). *F*, co-immunoprecipitation of C-terminally extended KCTD12 proteins with GABA<sub>B2</sub>. The indicated Myc-tagged KCTD proteins were co-expressed with GABA<sub>B1b</sub> and GABA<sub>B2</sub> (GB1 + GB2). Immunoprecipitation was performed with antibodies against GB2 and immunoprecipitates were analyzed by Western blot with antibodies against GB1, GB2, and the Myc epitope. The asterisk likely indicates a truncated fragment of the 12-Venus protein that is not co-immunoprecipitated with GB2. *Luc*, Luciferase; *Venus*, Venus-GFP variant.

and *D*;  $p < 0.01$ , compared with cells without KCTD). Finally, the converse substitution of these three residues in KCTD12 with the ones of KCTD16, but not the single amino acid substitution of Phe<sup>278</sup> by His, rendered the H1 domain of KCTD12 non-desensitizing (12KHR and 12H; Fig. 4, *E* and *F*;  $p < 0.001$ , compared with KCTD12). These experiments identify the motif T/NFLEQ in the H1 domain as a critical sequence element for KCTD-mediated desensitization.


**Molecular Evolution of the KCTD Subunits**—Our experiments show that the H1 domain is the functional unit respon-

sible for desensitization of the receptor response. The H1 domains of KCTD8 and 16 lack desensitizing properties due to one or three amino acid substitutions, respectively, in the T/NFLEQ motif. The H2 domains in KCTD8 and -16 have antagonistic effects and inhibit desensitization by the H1 domains. To understand how the KCTD proteins acquired these regulatory domains we investigated their evolutionary history.


Analysis of the human and zebrafish KCTD proteins revealed that they are distinct from voltage-gated K<sup>+</sup> channels, due to







**FIGURE 5. KCTD8, -12, -12b, and -16 recently diversified from a single common ancestor.** *A*, phylogenetic tree based on an amino acid alignment of the T1 domains of all KCTD proteins. Most KCTD proteins diverged deeply in time; however, a few groups have diverged more recently, including the group formed by KCTD8, -12, -12b, and -16 (box). TNFAIP1 and SHKBP1 are grouped with the KCTD proteins due to T1 domain-related sequences *B*, phylogenetic tree based on a nucleotide alignment of KCTD8, -12, -12b, and -16. For clarity, this tree is midpoint rooted. KCTD8, -12, -12b, and -16 evolved through the addition of the H2 domain after the origin of chordates and rapidly diversified into the KCTD8, -12, and -16 lineages, with the H2 domain being lost in KCTD12 and -12b. Of note, *D. rerio*, but not *M. musculus* retained part of the H2 domain in KCTD12b at the genomic level. In both *A* and *B*, the circles at each node indicate the posterior probabilities (the probability that the descendent proteins are more closely related to each other than to other proteins in the tree): *black*, greater than 95%; *gray*, between 75 and 95%; *white*, between 50 and 75%. Two copies of KCTD12 and 16 are present in *D. rerio*. These duplicate copies are also present in the genomes of other fish, due to an ancient genome duplication (not shown). *C*, sequence alignment of the GABA<sub>B2</sub> C-terminal domains of *M. musculus*, *D. rerio*, *D. melanogaster*, and *C. elegans*. Identical and similar amino acids are indicated by stars and dots, respectively. Amino acid Tyr<sup>902</sup>, which is critical for KCTD binding to GABA<sub>B2</sub> is only found in vertebrates and highlighted in *black*. *D*, functional model of vertebrate KCTD proteins. The T1 tetramerization domain binds to GABA<sub>B2</sub>, the H1 domain promotes the desensitization of GABA<sub>B</sub> responses and the H2 domain prevents desensitization when expressed *in cis* with a desensitizing H1 domain. TNFAIP1, Tumor necrosis factor  $\alpha$ -induced protein 1; SHKBP1, SH3 domain-containing kinase-binding protein 1.



**FIGURE 6. Alignment of vertebrate KCTD H2 domain amino acid sequences.** The C-terminal part of the H2 domain is retained in KCTD12b in most vertebrates, excluding placental mammals (e.g. *M. musculus*). Residues are numbered according to the H2 domain of *D. rerio* KCTD8. Conserved residues are highlighted: *dark gray*, present in more than 80% of the sequences; *light gray*, present in more than 50% of the sequences. The letters X in KCTD12b of *Gadua morhua* and *Takifugu rubripes* result from unspecified nucleotides in the genomic sequences. *M. musculus*, mouse; *D. rerio*, zebrafish; *G. morhua*, cod; *Oreochromis niloticus*, tilapia; *T. rubripes*, tiger pufferfish; *T. nigroviridis*, green-spotted pufferfish; *O. latipes*, medaka; *Xenopus tropicalis*, clawed frog; *Pelodiscus sinensis*, soft-shelled turtle; *Gallus gallus*, chicken; *Taeniopygia guttata*, zebra finch; *O. anatinus*, duck-billed platypus; *Sarcophilus harrisi*, tasmanian devil.

in the KCTD12 lineage. It remains to be addressed whether the residual H2 domain sequences in the KCTD12b genes of vertebrates are transcribed and translated. In this respect, it is interesting to note that all H2 domain sequences analyzed, including those of KCTD8 and -16, are encoded by a separate exon downstream of the exon encoding the T1 and H1 domains. Therefore

it is possible that multiple KCTD8, -16, or -12b variants are generated by alternative splicing. In conclusion, our phylogenetic analysis shows that desensitizing KCTD12 and -12b proteins evolved from non-desensitizing KCTD proteins by disposal of the inhibitory H2 domains and acquisition of the T/NFLEQ motif in their desensitizing H1 domains.



## DISCUSSION

Association of auxiliary KCTD8, -12, -12b, and -16 subunits with principal GABA<sub>B</sub> receptor subunits was recently shown to generate molecularly and functionally distinct receptor subtypes (5, 6, 9, 28). The four KCTD proteins are built from obligatory T1 and H1 domains and optional H2 domains. The T1 domains bind as tetramers to the GABA<sub>B2</sub> subunit and thus are crucial for formation of the receptor complex. No functional roles have been assigned to the H1 and H2 domains of the KCTD subunits yet. In this study we show that the H1 and H2 domains have opposite effects on fast desensitization of the receptor response. H1 domains containing the T/NFLEQ motif mediate the desensitization while the H2 domains antagonize this desensitization. The antagonistic effect of the H2 domain is only observed when the domain is expressed *in cis* with the H1 domain but not when the H2 domain is expressed as a separate protein *in trans* together with KCTD12. This suggests that the H2 domain does not inhibit desensitization through the binding to a specific site. More likely, the H2 domain acts by sterically hindering the binding of the H1 domain to a downstream effector responsible for fast desensitization such as, for example, proteins involved in G-protein signaling. In agreement with a steric hindrance of desensitization by the H2 domain KCTD-unrelated protein domains can substitute for the H2 domain and prevent KCTD12-mediated desensitization when tethered to the C terminus of KCTD12. It is unclear whether desensitizing and non-desensitizing KCTD proteins can simultaneously bind to the same receptor complex (6). If this is the case, our results suggest that the H2 domains of KCTD8 or -16 will be unable to inhibit desensitization by KCTD12 or -12b *in trans*. From an evolutionary perspective, it appears that the H2 domain was first acquired in an ancestral KCTD protein with non-desensitizing properties and subsequently lost in KCTD12 and -12b. It is therefore unlikely that the prime function of the H2 domain in KCTD8 and -16 is to antagonize desensitization.

KCTD12 and -12b evolved the T/NFLEQ motif within their H1 domain, which is necessary for KCTD-mediated desensitization of the receptor response. One to three amino acid substitutions within this motif can turn a desensitizing into a non-desensitizing H1 domain and *vice versa*. Secondary structure analysis predicts that the motif is part of a helix with amphipathic characteristics. It appears that an excess of positively charged amino acids within this helix, such as Arg, His, and Lys in KCTD16, is not permissive for desensitization. It is possible that these positively charged amino acids interact with negatively charged phospholipids of the plasma membrane and reduce the mobility of the helix. In addition, it appears that specific residues at the interface between the hydrophilic and the hydrophobic side of the helix are crucial for desensitization. Thus, substitution of Tyr<sup>278</sup> with Phe was sufficient to render the H1 domain of KCTD8 desensitizing. Interestingly, amphipathic helices are widely found in proteins participating in membrane-associated biological processes. In particular, amphipathic helices within GPCRs, G-protein subunits or naturally occurring peptides were shown to regulate the G-protein activation-deactivation cycle (29–34). It is thus possible that the amphipathic helix in the H1 domain of KCTD12 and -12b directly regulates the

G-protein that binds in its proximity to GABA<sub>B2</sub> (35–37). However, no binding partners for the H1 domain have yet been identified.

Our evolutionary analysis shows that receptor subtypes owing to auxiliary KCTD subunits emerged with the appearance of vertebrates. In this respect it is interesting to note that GABA<sub>B1</sub> subunit isoforms regulating axonal *versus* dendritic distribution of GABA<sub>B</sub> receptors (38) also first evolved in vertebrates. This suggests that it became essential to control GABA<sub>B</sub> receptor desensitization with the emergence of localized signaling. KCTD12 and -16 proteins appear to be present in pre- and postsynaptic GABA<sub>B</sub> receptors (6) albeit to differing degrees (9). Biochemical data support that certain GABA<sub>B</sub> receptors in the brain contain KCTD12 and others KCTD16 (6). However, whether association with specific KCTDs is responsible for the differences in desensitization between pre- and postsynaptic GABA<sub>B</sub> receptors remains to be addressed (39–41). In conclusion, whereas the heteromeric nature and the activation mechanism of the GABA<sub>B</sub> core receptor are conserved in evolution (42–46), only the vertebrate GABA<sub>B</sub> receptors recruit functionally distinct auxiliary KCTD subunits and generate receptor subtypes.

*Acknowledgments*—We thank Audrée Pinard and Klara Ivankova for critical reading of the manuscript.

## REFERENCES

- Bettler, B., Kaupmann, K., Mosbacher, J., and Gassmann, M. (2004) Molecular structure and physiological functions of GABA<sub>B</sub> receptors. *Physiol. Rev.* **84**, 835–867
- Bowery, N. G., Bettler, B., Froestl, W., Gallagher, J. P., Marshall, F., Raiteri, M., Bonner, T. I., and Enna, S. J. (2002) International Union of Pharmacology. XXXIII. Mammalian  $\gamma$ -aminobutyric acid<sub>B</sub> receptors: structure and function. *Pharmacol. Rev.* **54**, 247–264
- Chalifoux, J. R., and Carter, A. G. (2011) GABA<sub>B</sub> receptor modulation of synaptic function. *Curr. Opin. Neurobiol.* **21**, 339–344
- Couve, A., Moss, S. J., and Pangalos, M. N. (2000) GABA<sub>B</sub> receptors: a new paradigm in G protein signaling. *Mol. Cell. Neurosci.* **16**, 296–312
- Gassmann, M., and Bettler, B. (2012) Regulation of neuronal GABA<sub>B</sub> receptor functions by subunit composition. *Nat. Rev. Neurosci.* **13**, 380–394
- Schwenk, J., Metz, M., Zolles, G., Turecek, R., Fritzius, T., Bildl, W., Tarusawa, E., Kulik, A., Unger, A., Ivankova, K., Seddik, R., Tiao, J. Y., Rajalu, M., Trojanova, J., Rohde, V., Gassmann, M., Schulte, U., Fakler, B., and Bettler, B. (2010) Native GABA<sub>B</sub> receptors are heteromultimers with a family of auxiliary subunits. *Nature* **465**, 231–235
- Sickmann, T., and Alzheimer, C. (2003) Short-term desensitization of G-protein-activated, inwardly rectifying K<sup>+</sup> (GIRK) currents in pyramidal neurons of rat neocortex. *J. Neurophysiol.* **90**, 2494–2503
- Sodickson, D. L., and Bean, B. P. (1996) GABA<sub>B</sub> receptor-activated inwardly rectifying potassium current in dissociated hippocampal CA3 neurons. *J. Neurosci.* **16**, 6374–6385
- Metz, M., Gassmann, M., Fakler, B., Scharen-Wiemers, N., and Bettler, B. (2011) Distribution of the auxiliary GABA<sub>B</sub> receptor subunits KCTD8, 12, 12b, and 16 in the mouse brain. *J. Comp. Neurol.* **519**, 1435–1454
- Perroy, J., Adam, L., Qanbar, R., Chénier, S., and Bouvier, M. (2003) Phosphorylation-independent desensitization of GABA<sub>B</sub> receptor by GRK4. *EMBO J.* **22**, 3816–3824
- Labouèbe, G., Lomazzi, M., Cruz, H. G., Creton, C., Luján, R., Li, M., Yanagawa, Y., Obata, K., Watanabe, M., Wickman, K., Boyer, S. B., Slesinger, P. A., and Lüscher, C. (2007) RGS2 modulates coupling between GABA<sub>B</sub> receptors and GIRK channels in dopamine neurons of the ventral tegmental area. *Nat. Neurosci.* **10**, 1559–1568

12. Maity, B., Stewart, A., Yang, J., Loo, L., Sheff, D., Shepherd, A. J., Mohapatra, D. P., and Fisher, R. A. (2012) Regulator of G protein signaling 6 (RGS6) protein ensures coordination of motor movement by modulating GABA<sub>B</sub> receptor signaling. *J. Biol. Chem.* **287**, 4972–4981
13. Mutneja, M., Berton, F., Suen, K. F., Lüscher, C., and Slesinger, P. A. (2005) Endogenous RGS proteins enhance acute desensitization of GABA<sub>B</sub> receptor-activated GIRK currents in HEK-293T cells. *Pflugers Arch.* **450**, 61–73
14. Xie, K., Allen, K. L., Kourrich, S., Colón-Saez, J., Thomas, M. J., Wickman, K., and Martemyanov, K. A. (2010) Gβ5 recruits R7 RGS proteins to GIRK channels to regulate the timing of neuronal inhibitory signaling. *Nat. Neurosci.* **13**, 661–663
15. Couve, A., Thomas, P., Calver, A. R., Hirst, W. D., Pangalos, M. N., Walsh, F. S., Smart, T. G., and Moss, S. J. (2002) Cyclic AMP-dependent protein kinase phosphorylation facilitates GABA<sub>B</sub> receptor-effector coupling. *Nat. Neurosci.* **5**, 415–424
16. Fairfax, B. P., Pitcher, J. A., Scott, M. G., Calver, A. R., Pangalos, M. N., Moss, S. J., and Couve, A. (2004) Phosphorylation and chronic agonist treatment atypically modulate GABA<sub>B</sub> receptor cell surface stability. *J. Biol. Chem.* **279**, 12565–12573
17. Bayón, Y., Trinidad, A. G., de la Puerta, M. L., Del Carmen Rodríguez, M., Bogetz, J., Rojas, A., De Pereda, J. M., Rahmouni, S., Williams, S., Matsuzawa, S., Reed, J. C., Crespo, M. S., Mustelin, T., and Alonso, A. (2008) KCTD5, a putative substrate adaptor for cullin3 ubiquitin ligases. *FEBS J.* **275**, 3900–3910
18. Stogios, P. J., Downs, G. S., Jauhal, J. J., Nandra, S. K., and Privé, G. G. (2005) Sequence and structural analysis of BTB domain proteins. *Genome Biol.* **6**, R82
19. Bixby, K. A., Nanao, M. H., Shen, N. V., Kreuzsch, A., Bellamy, H., Pfaffinger, P. J., and Choe, S. (1999) Zn<sup>2+</sup>-binding and molecular determinants of tetramerization in voltage-gated K<sup>+</sup> channels. *Nat. Struct. Biol.* **6**, 38–43
20. Horton, R. M., Cai, Z. L., Ho, S. N., and Pease, L. R. (1990) Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. *BioTechniques* **8**, 528–535
21. Urwyler, S., Mosbacher, J., Lingenhoeck, K., Heid, J., Hofstetter, K., Froestl, W., Bettler, B., and Kaupmann, K. (2001) Positive allosteric modulation of native and recombinant  $\gamma$ -aminobutyric acid<sub>B</sub> receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. *Mol. Pharmacol.* **60**, 963–971
22. Wischmeyer, E., Döring, F., Spauschus, A., Thomzig, A., Veh, R., and Karschin, A. (1997) Subunit interactions in the assembly of neuronal Kir3.0 inwardly rectifying K<sup>+</sup> channels. *Mol. Cell. Neurosci.* **9**, 194–206
23. Edgar, R. C. (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res.* **32**, 1792–1797
24. Ronquist, F., and Huelsenbeck, J. P. (2003) MrBayes 3: Bayesian phylogenetic inference under mixed models. *Bioinformatics* **19**, 1572–1574
25. Castresana, J. (2000) Selection of conserved blocks from multiple alignments for their use in phylogenetic analysis. *Mol. Biol. Evol.* **17**, 540–552
26. Gamse, J. T., Kuan, Y. S., Macurak, M., Brösamle, C., Thisse, B., Thisse, C., and Halpern, M. E. (2005) Directional asymmetry of the zebrafish epithalamus guides dorsoventral innervation of the midbrain target. *Development* **132**, 4869–4881
27. Taylor, R. W., Qi, J. Y., Talaga, A. K., Ma, T. P., Pan, L., Bartholomew, C. R., Klionsky, D. J., Moens, C. B., and Gamse, J. T. (2011) Asymmetric inhibition of Ulk2 causes left-right differences in habenular neuropil formation. *J. Neurosci.* **31**, 9869–9878
28. Bartoi, T., Rigbolt, K. T., Du, D., Köhr, G., Blagoev, B., and Kornau, H. C. (2010) GABA<sub>B</sub> receptor constituents revealed by tandem affinity purification from transgenic mice. *J. Biol. Chem.* **285**, 20625–20633
29. Hamm, H. E. (2001) How activated receptors couple to G proteins. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 4819–4821
30. Johnston, C. A., Willard, F. S., Jezyk, M. R., Fredericks, Z., Bodor, E. T., Jones, M. B., Blaesius, R., Watts, V. J., Harden, T. K., Sondek, J., Ramer, J. K., and Siderovski, D. P. (2005) Structure of Gα<sub>i1</sub> bound to a GDP-selective peptide provides insight into guanine nucleotide exchange. *Structure* **13**, 1069–1080
31. Kisselev, O. G., and Downs, M. A. (2003) Rhodopsin controls a conformational switch on the transducin  $\gamma$  subunit. *Structure* **11**, 367–373
32. Kisselev, O. G., Kao, J., Ponder, J. W., Fann, Y. C., Gautam, N., and Marshall, G. R. (1998) Light-activated rhodopsin induces structural binding motif in G protein  $\alpha$  subunit. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 4270–4275
33. Kusunoki, H., Wakamatsu, K., Sato, K., Miyazawa, T., and Kohno, T. (1998) G protein-bound conformation of mastoparan-X: heteronuclear multidimensional transferred nuclear overhauser effect analysis of peptide uniformly enriched with <sup>13</sup>C and <sup>15</sup>N. *Biochemistry* **37**, 4782–4790
34. Okuno, T., Ago, H., Terawaki, K., Miyano, M., Shimizu, T., and Yokomizo, T. (2003) Helix 8 of the leukotriene B<sub>4</sub> receptor is required for the conformational change to the low affinity state after G-protein activation. *J. Biol. Chem.* **278**, 41500–41509
35. Duthey, B., Caudron, S., Perroy, J., Bettler, B., Fagni, L., Pin, J. P., and Prézeau, L. (2002) A single subunit (GB2) is required for G-protein activation by the heterodimeric GABA<sub>B</sub> receptor. *J. Biol. Chem.* **277**, 3236–3241
36. Galvez, T., Duthey, B., Kniazeff, J., Blahos, J., Rovelli, G., Bettler, B., Prézeau, L., and Pin, J. P. (2001) Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA<sub>B</sub> receptor function. *EMBO J.* **20**, 2152–2159
37. Robbins, M. J., Calver, A. R., Filippov, A. K., Hirst, W. D., Russell, R. B., Wood, M. D., Nasir, S., Couve, A., Brown, D. A., Moss, S. J., and Pangalos, M. N. (2001) GABA<sub>B2</sub> is essential for G-protein coupling of the GABA<sub>B</sub> receptor heterodimer. *J. Neurosci.* **21**, 8043–8052
38. Biermann, B., Ivankova-Susankova, K., Bradaia, A., Abdel Aziz, S., Besseyrias, V., Kapfhammer, J. P., Missler, M., Gassmann, M., and Bettler, B. (2010) The Sushi domains of GABA<sub>B</sub> receptors function as axonal targeting signals. *J. Neurosci.* **30**, 1385–1394
39. Cruz, H. G., Ivanova, T., Lunn, M. L., Stoffel, M., Slesinger, P. A., and Lüscher, C. (2004) Bi-directional effects of GABA<sub>B</sub> receptor agonists on the mesolimbic dopamine system. *Nat. Neurosci.* **7**, 153–159
40. Pennock, R. L., Dicken, M. S., and Hentges, S. T. (2012) Multiple inhibitory G-protein-coupled receptors resist acute desensitization in the presynaptic but not postsynaptic compartments of neurons. *J. Neurosci.* **32**, 10192–10200
41. Wetherington, J. P., and Lambert, N. A. (2002) GABA<sub>B</sub> receptor activation desensitizes postsynaptic GABA<sub>B</sub> and A<sub>1</sub> adenosine responses in rat hippocampal neurons. *J. Physiol.* **544**, 459–467
42. Dittman, J. S., and Kaplan, J. M. (2008) Behavioral impact of neurotransmitter-activated G-protein-coupled receptors: muscarinic and GABA<sub>B</sub> receptors regulate *Caenorhabditis elegans* locomotion. *J. Neurosci.* **28**, 7104–7112
43. Mezler, M., Müller, T., and Raming, K. (2001) Cloning and functional expression of GABA<sub>B</sub> receptors from *Drosophila*. *Eur. J. Neurosci.* **13**, 477–486
44. Schultheis, C., Brauner, M., Liewald, J. F., and Gottschalk, A. (2011) Optogenetic analysis of GABA<sub>B</sub> receptor signaling in *Caenorhabditis elegans* motor neurons. *J. Neurophysiol.* **106**, 817–827
45. Vashlishan, A. B., Madison, J. M., Dybbs, M., Bai, J., Sieburth, D., Ch'ng, Q., Tavazoie, M., and Kaplan, J. M. (2008) An RNAi screen identifies genes that regulate GABA synapses. *Neuron* **58**, 346–361
46. Wilson, R. I., and Laurent, G. (2005) Role of GABAergic inhibition in shaping odor-evoked spatiotemporal patterns in the *Drosophila* antennal lobe. *J. Neurosci.* **25**, 9069–9079